MrTAC-8
MrTAC-8, methylarginine-targeting chimera (MrTAC), is a BRD4 degrader with DC50 values of 46 nM in HeLa cells. MrTAC-8 recruits PRMT1, PRMT3, PRMT4, PRMT5, and PRMT7 to target proteins, inducing arginine methylation that triggers lysosomal degradation. MrTAC-8 degrades proteins across diverse subcellular localizations and independent of native proteolytic routes. MrTAC-8 can be used for the research of cervical cancer, glioblastoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C54H65ClN10O6S
- 分子量:1017.68
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
IC50 & Target
[1]|
BRD4 |
体外実験
MrTAC-8 (0.01 nM-10 μM; 24 h) potently induces lysosomal degradation of endogenous BRD4 via catalytically active PRMT5 recruitment, with DC50 values of 46 nM in HeLa cells, 67 nM in U87 cells, and 4.8 μM in HEK293 cells[1].
MrTAC-8 (1 μM; 2 h) blocks BRD4 degradation in HeLa cells when pre-treated with lysosomal inhibitors bafilomycin and Chloroquine (HY-17589A), restoring BRD4 levels to 110% of DMSO control[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HEK293, HeLa, U87 human cancer cells
-
Concentration:0.01 nM; 0.1 nM; 1 nM; 10 nM; 100 nM; 1 μM; 10 μM
-
Incubation Time:24 h
-
Result:Reduced BRD4 levels to 39% of DMSO control in HEK293 cells at 1 μM.
Reduced BRD4 levels to 13% of DMSO control in HEK293 cells at 10 μM.
Demonstrated cell line-specific potency, with DC50 values of 46 nM in HeLa cells, 67 nM in U87 cells, and 4.8 μM in HEK293 cells.
-
Cell Line:HeLa human cervical cancer cells
-
Concentration:1 μM plus 500 nM bafilomycin and 10 μM Chloroquine
-
Incubation Time:2 h
-
Result:Blocked BRD4 degradation when pre-treated with lysosomal inhibitors bafilomycin and Chloroquine, restoring BRD4 levels to 110% of DMSO control.
Reduced BRD4 levels to 100% of DMSO control in cells expressing catalytically dead (E444Q) PRMT5 at 1 μM, compared to 15% reduction in cells expressing wild-type PRMT5.
Enriched BRD4 in SDMA-positive fractions after treatment, confirming proximity-induced arginine methylation.
化学情報
-
分子量 1017.68
-
分子式 C54H65ClN10O6S
-
SMILES
O=C(NCCC1CCN(CC(C(NCCOCCNC(C[C@@H]2N=C(C3=CC=C(Cl)C=C3)C4=C(SC(C)=C4C)N5C(C)=NN=C25)=O)=O)=C)CC1)C6=CC=C(C(NC[C@H](O)CN7CCC8=CC=CC=C8C7)=O)C=C6
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
MrTAC-8 関連分類
HY-183061 関連分類
Powered by Bioz